Psychologists in Lake Havasu City, AZ Accepting Medicare
6 Psychologists found. Showing 1 - 6
 Mrs. Belinda Gail Anders, MA Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 2200 Havasupai Blvd, Lake Havasu City, AZ 86403 Phone: 928-505-6911 Fax: 928-505-6991 |
 Dr. Ronald Glenn Smith, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 55 Lake Havasu Ave S, Ste. F-365, Lake Havasu City, AZ 86403 Phone: 928-854-2373 Fax: 928-680-9811 |
J Maxie Elliott Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 2200 Havasupai Blvd, Lake Havasu City, AZ 86403 Phone: 928-505-6911 |
Mrs. Kara Susan Skowera Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 2200 Havasupai Blvd, Lake Havasu City, AZ 86403 Phone: 928-505-6911 Fax: 928-505-6991 |
Kristin Lee Carbone-kebble Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 480 Mate Ln, Lake Havasu City, AZ 86406 Phone: 928-916-3134 |
Mr. Douglas George Pheling, MA Psychologist - School Medicare: Not Enrolled in Medicare Practice Location: 2200 Havasupai Blvd, Lake Havasu City, AZ 86403 Phone: 928-505-6911 Fax: 928-505-6991 |
News Archive
AMGA releases comments on preliminary proposals for Stage 2 Meaningful Use objectives
The American Medical Group Association, a trade association representing multispecialty medical groups and other organized systems of care, today released its comments on a request for information from the Health Information Technology Policy Committee on its preliminary proposals for Stage 2 Meaningful Use objectives.
Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV
Vertex Pharmaceuticals Incorporated today announced positive interim results from an ongoing Phase 2 study designed to evaluate the safety and tolerability of INCIVEK (telaprevir) tablets in combination with pegylated-interferon and ribavirin in people who are co-infected with chronic genotype 1 hepatitis C (HCV) and human immunodeficiency virus.
Maternal-fetal interface yields intriguing clues to how it battles SARS-CoV-2
Scientists have hypothesized that the number of immune cells and the amount of cytokines produced in response to SARS-CoV-2 infection in pregnant women change in accordance with the timing of maternal infection in pregnancy. This study is available on the bioRxiv* preprint server.
Optimized SARS-CoV-2 vaccine candidate could be less reactogenic, say researchers
A new study, released as a preprint on the bioRxiv* server, reports an optimized coronavirus disease 2019 (COVID-19) vaccine candidate, which, claim the researchers, may be less likely to produce reactions like fevers. It may also have increased protective potential against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen that causes COVID-19.
Agena Bioscience releases LungFUSION Panel to identify gene fusions in NSCLC tumors
Agena Bioscience today released the LungFUSION Panel for rapid and sensitive identification of oncogenic ALK, RET, and ROS1 gene fusions in non-small cell lung cancer tumors.
› Verified 9 days ago
Pharmacists
Dentists
Counselors
Occupational Therapists
Clinical Social Workers
Psychologists